This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ESMO 2021
Presentations

Ladiratuzumab Vedotin | Solid Tumors | Abstract #972
Open-Label, Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors (SGNLVA-005, Trial in Progress)

Enfortumab Vedotin | Urothelial Carcinoma | Abstract #3557
Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line (1L) Therapies for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC)

Tucatinib | Breast Cancer | Abstract #1770
HER2CLIMB-04: Phase 2 Trial of Tucatinib + Trastuzumab Deruxtecan in Patients with HER2+ Locally Advanced or Metastatic Breast Cancer With and Without Brain Metastases (Trial in Progress)

Tucatinib | Gastrointestinal Carcinoma | Abstract #1092
MOUNTAINEER-02: Phase 2/3 Study of Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel in Previously Treated HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC): (Trial in Progress)

SGN-B6A | Solid Tumors | Abstract #2946
A First-In-Human Trial of the Integrin Beta-6-Targeted Antibody-Drug Conjugate, SGN-B6A, in Patients With Advanced Solid Tumors (SGNB6A-001, Trial in Progress)

Brentuximab Vedotin | NSCLC or Cutaneous Melanoma | Abstract #3027
A Phase 2 Trial of Pembrolizumab and Brentuximab Vedotin in Patients With Metastatic Solid Malignancies After Progression on Prior Programmed Cell Death Protein-1 Inhibitors (SGN35-033, Trial in Progress)

SGN-STNV | Solid Tumors | Abstract #3325
A Phase 1 Study of SGN-STNV, A Novel Antibody-Drug Conjugate Targeting Sialyl-Thomsen-Nouveau Antigen (STN), in Adults With Advanced Solid Tumors (SGNSTNV-001, Trial in Progress)

Enfortumab Vedotin | Urothelial Carcinoma | Abstract #3252
Treatment Patterns Among Patients With Advanced Urothelial Carcinoma (aUC) in the US

Tucatinib | Gastrointestinal Cancers | Abstract #541
Phase 1B/2 Open-Label, Dose Escalation and Expansion Trial of Tucatinib in Combination with Trastuzumab and Oxaliplatin-Based Chemotherapy in Patients With Unresectable or Metastatic HER2+ Gastrointestinal Cancers (Trial in Progress)

Tucatinib | Solid Tumors | Abstract #1003
SGNTUC-019: Phase 2 Basket Study of Tucatinib and Trastuzumab in Previously Treated Solid Tumors With HER2 Alterations (Trial in Progress)

SEA-TGT | Advanced Malignancies | Abstract #3661
Phase 1 Study of Effector Function Enhanced Monoclonal Antibody, SEA-TGT, in Advanced Malignancies (SGNTGT-001, Trial in Progress)

Tucatinib | Colorectal Cancer | Abstract #3027
Characteristics and Treatment Patterns Among Patients With HER2-Amplified Advanced/Metastatic Colorectal Cancer (mCRC): A Clinical-Genomic Database Study

Ladiratuzumab Vedotin | Breast Cancer | Abstract #1378
Weekly Ladiratuzumab Vedotin Monotherapy for Metastatic Triple Negative Breast Cancer

Tisotumab Vedotin | Solid Tumors | Abstract #646
innovaTV 207: New Dosing Cohort in the Open Label Phase 2 Study of Tisotumab Vedotin in Solid Tumors

Enfortumab Vedotin | Urothelial Carcinoma | Abstract #1151
Analysis of Hard-to-Treat Subgroups From EV-301, a Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy for Previously Treated Advanced Urothelial Carcinoma

Tisotumab Vedotin | Cervical Cancer | Abstract #3107
Tisotumab Vedotin + Carboplatin in First-Line or + Pembrolizumab in Previously Treated Recurrent/Metastatic Cervical Cancer: Interim Results of ENGOT-Cx8/GOG-3024/innovaTV 205